Current update on imaging for pancreatic neuroendocrine neoplasms

doi:10.5306/wjco.v12.i10.897

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5269)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-2) series.

Item

Count

PDF

426

WORD

102

HTML

3282

Figures (1-5)

223

Tables (1-2)

244

Sum=4277

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

405

Download

587

Sum=992

Oct 24, 2021 (publication date) through Nov 8, 2024

Times Cited of This Article

Times Cited (10)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Clin Oncol. Oct 24, 2021; 12(10): 897-911
Published online Oct 24, 2021. doi: 10.5306/wjco.v12.i10.897

Table 1 Comparison of 2010 and 2017 World Health Organization classification system for pancreatic neuroendocrine tumors

WHO 2010 Classification system	WHO 2017 Classification system	Ki-67 index (%)	Mitotic index¹
Well-differentiated PanNET G1	Well-differentiated PanNET G1	< 3	< 2
Well-differentiated PanNET G2	Well-differentiated PanNET G2	3-20	2-20
	Well-differentiated PanNET G3	> 20	> 20
Poorly-differentiated PanNEC G3 (i.e. small cell carcinoma, large cell carcinoma)	Poorly-differentiated PanNEC G3 (i.e. small cell carcinoma, large cell carcinoma)	> 20	> 20
MiNEN	MANEC

¹Per 10 high-power fields. WHO: World Health Organization; PanNEN: Pancreatic neuroendocrine neoplasms; PanNET: Pancreatic neuroendocrine tumors; PanNEC: Pancreatic neuroendocrine carcinomas; MiNEN: mixed neuroendocrine-nonneuroendocrine neoplasms; MANEC: Mixed adenoneuroendocrine carcinomas.

Table 2 Imaging features of grade 3 pancreatic neuroendocrine tumors vs grade 3 pancreatic neuroendocrine carcinomas

Grade 3 PanNET	Grade 3 PanNEC
Smaller, more defined lesions	Larger, ill-defined lesions
Absence of ductal dilation or metastatic disease	Ductal dilation or metastatic disease
Low to moderate homogeneous enhancement on arterial phase imaging	Heterogeneous or rim-like enhancement on arterial phase imaging
Hypointense on delayed phase imaging	Atypical persistence of enhancement on delayed phase imaging
Higher ADC values	Signal hyperintensity on diffusion-weighted MRI and lower ADC value
Low uptake on ¹⁸F-FDG PET/CT	High uptake on ¹⁸F-FDG PET/CT
Moderate uptake on ⁶⁸Ga-DOTATATE PET/CT	Low uptake on ⁶⁸Ga-DOTATATE PET/CT

MRI: Magnetic resonance imaging; ADC: Apparent diffusion coefficient; PanNET: Pancreatic neuroendocrine tumors; PanNEC: Pancreatic neuroendocrine carcinomas; ADC: Apparent diffusion coefficient; ¹⁸F-FDG: Fluorine-18 fluorodeoxyglucose; PET/CT: positron emission tomography/computed tomography;⁶⁸Ga-DOTATATE: Gallium-68 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid–octreotate.

Citation: Segaran N, Devine C, Wang M, Ganeshan D. Current update on imaging for pancreatic neuroendocrine neoplasms. World J Clin Oncol 2021; 12(10): 897-911
URL: https://www.wjgnet.com/2218-4333/full/v12/i10/897.htm
DOI: https://dx.doi.org/10.5306/wjco.v12.i10.897